Publications by authors named "Colin Hayward"
Article Synopsis
- The study investigates the use of a radioactive monoclonal antibody, [Zr]Zr-girentuximab, for non-invasive detection of clear-cell renal cell carcinoma in patients with renal masses.
- Conducted across 36 sites in nine countries, the phase 3 trial involved 332 enrolled patients with suspicious renal masses, who received the antibody followed by PET-CT imaging.
- The primary goals of the trial were to assess the sensitivity and specificity of the imaging technique using histopathological confirmation as the standard, with findings from 300 patients eventually analyzed.
Background: Glioblastoma (GBM), the most common malignant brain tumor, is associated with devastating outcomes. IPAX-1 was a multicenter, open-label, single-arm phase I study to evaluate carrier-added 4--[I]iodo-phenylalanine ([I]IPA) plus external radiation therapy (XRT) in recurrent GBM.
Methods: A total of 10 adults with recurrent GBM who had received first-line debulking surgery plus radio-chemotherapy, were randomized to a single-dose regimen (1f; I-IPA 2 GBq before XRT); a fractionated parallel dose regimen (3f-p; 3 I-IPA 670 MBq fractions, in parallel with second-line XRT), or a fractionated sequential dose regimen (3f-s; 3 I-IPA 670 MBq fractions before and after XRT).
Background: PET/CT imaging with Zirconium-89 labeled [89Zr]Zr-DFO-girentuximab, which targets tumor antigen CAIX, may aid in the differentiation and characterization of clear cell renal cell carcinomas (RCC) and other renal and extrarenal lesions, and has been studied in European and American cohorts. We report results from a phase I study that evaluated the safety profile, biodistribution, and dosimetry of [89Zr]Zr-DFO-girentuximab in Japanese patients with suspected RCC.
Methods: Eligible adult patients received 37 MBq (± 10%; 10 mg mass dose) of intravenous [89Zr]Zr-DFO-girentuximab.
Article Synopsis
- Epoetin therapy can slightly increase the risk of thromboembolic events (TEEs) in cancer patients, but the causal relationship remains unclear.
- A meta-analysis of 9 trials showed that 5.9% of patients on epoetin beta experienced TEEs, compared to 4.2% in the control group, with no significant increase in mortality rates between the two.
- Higher increases in hemoglobin (Hb) levels correlated with a reduced risk of TEEs, while higher baseline Hb levels were linked to an increased risk, suggesting that careful monitoring of Hb is essential in epoetin beta treatment.
In vitro and animal model studies have shown erythropoietin receptor (Epo-R) mRNA and/or protein may be present in a range of human tumours and cancer cell lines, and erythropoiesis-stimulating agents (ESAs) have been reported to have tumour cell growth-modulating effects. Following a review of the literature, we conclude that considerations must be made when interpreting data from the preclinical studies. First, supraphysiological doses of ESAs were usually used.
View Article and Find Full Text PDFThis retrospective observational survey assessed, in a routine clinical practice setting, the modalities of treatment with recombinant erythropoietic agents: alpha erythropoietic agents [epoetin alpha (Eprex) and darbepoetin alpha (Aranesp)] and epoetin beta (NeoRecormon). Evolution of haematological response parameters such as haemoglobin (Hb) during treatment of anaemic patients with cancer were contrasted for the different agents. Records of 125 consecutive adult cancer patients (42 epoetin alpha, 40 epoetin beta, 43 darbepoetin alpha) receiving chemotherapy and erythropoietic treatment for anaemia, and treated between September 2003 and February 2004, were analysed.
View Article and Find Full Text PDF